Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist

Antonio Martinez-Lopez, PhD, MD,a,b Carlos Cuenca-Barrales, MD,b Trinidad Montero-Vilchez, MD,a Alejandro Molina-Leyva, PhD, MD,a,b and Salvador Arias-Santiago, PhD, MDa,b,c
Granada, Spain

The new coronavirus, severe acute respiratory syndrome coronavirus 2, is spreading rapidly worldwide. To date, there are no proven effective therapies for this virus. Knowledge about SARS-CoV-2 virology is rapidly increasing, and a large number of potential drug targets are being investigated.1 Currently, infection management is mainly supportive, and common drugs prescribed for infection control include antimalarials (chloroquine and hydroxychloroquine), antivirals (lopinavir/ritonavir, ribavirin with or without interferon, oseltamivir, remdesivir, favipiravir, and darunavir), and treatments for complications (matinib, tocilizumab, anakinra, immunoglobulins, corticosteroids, colchicine and low molecular weight heparins) are analyzed. Information regarding possible skin reactions, their frequency, management, and key points for differential diagnosis are presented. (J Am Acad Dermatol 2020;83:1738-48.)

Key words: COVID-19 drug treatment; drug eruptions; drug-related side effects and adverse reactions; review.

The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide. To date, there are no proven effective therapies for this virus. Knowledge about SARS-CoV-2 virology is rapidly increasing, and a large number of potential drug targets are being investigated.1 Currently, infection management is mainly supportive, and common drugs prescribed for infection control include antimalarials (chloroquine and hydroxychloroquine), lopinavir/ritonavir, ribavirin, interferon, oseltamivir, remdesivir, favipiravir, and darunavir. Drugs prescribed for complications associated with viral infections include anticytokines (mainly interleukin [IL] 6 blockers and anakinra), matinib, corticosteroids, colchicine, heparins, immunoglobulins, and hyperimmune plasma.2

Cutaneous manifestations have recently been described in patients with the new coronavirus infection, similar to cutaneous involvement occurring in common viral infections.3-5 A recently published nationwide consensus study in Spain has widely described these manifestations in a prospective study with 375 cases. In this case collection survey, authors described 5 clinical patterns: acral areas with erythema-edema associated with some vesicles or pustules (pseudo-chilblain lesions), maculopapular eruptions, urticaria, other vesicular lesions (monomorphic disseminated vesicular lesions and acral vesicular-pustulous lesions), and livedo or necrosis.6

The diagnosis of cutaneous manifestations in patients with SARS-CoV-2 infection is challenging for dermatologists.7,8 It remains unclear whether these lesions are related to the virus. Skin diseases not related to coronavirus, other seasonal viral infections, and drug reactions should be considered in the differential diagnosis, especially in those patients with nonspecific manifestations such as urticaria or maculopapular eruptions. However, some features may help distinguish COVID-19 cutaneous lesions from drug-related ones. Urticarial
lesions and maculopapular eruptions in SARS-CoV-2 infections usually appear at the same time as the systemic symptoms, whereas drug adverse reactions are likely to arise hours to days after the start of the treatment.\textsuperscript{5,20} The aim of this review is to provide dermatologists with an overview of the cutaneous adverse effects associated with the most frequently prescribed drugs in patients with COVID-19, serving as a guide to assist dermatologists and other physicians in differential diagnosis.

**ANTIMALARIALS**

Hydroxychloroquine and chloroquine are antimalarials that have been widely used in the treatment of some chronic inflammatory diseases. They are currently being investigated in more than 160 clinical trials\textsuperscript{10} and have been approved for the treatment of COVID-19 by the US Food and Drug Administration (FDA) as an Emergency Use Authorization and by the European Medicines Agency for hospitalized patients in the context of clinical trials or as part of national emergency programs.\textsuperscript{11,12} Although their mechanisms of action against SARS-CoV-2 are not fully understood, both drugs may change the pH at the cell membrane surface and inhibit viral fusion and glycosylation of viral proteins. Moreover, hydroxychloroquine can also inhibit nucleic acid replication and viral assembly.\textsuperscript{13,14} Despite the lack of high-quality scientific articles, several studies have shown improved survival of patients with COVID-19 who were treated with antimalarials. Although 2 studies showed an increased mortality in patients treated with antimalarials, these articles have been retracted because the authors cannot vouch for the veracity of the data.\textsuperscript{15,16}

Both treatments are generally well tolerated, with retinopathy being the best known adverse effect. However, cutaneous adverse events might appear in up to 11.5% of patients,\textsuperscript{17} and some of them can be mistaken for skin manifestations of SARS-CoV-2, especially those with maculopapular rash or exanthematous reactions. This itchy maculopapular eruption tends to appear 2 weeks after the start of the treatment, mainly on the trunk and limbs, and may mean that treatment has to be stopped in some patients.\textsuperscript{18-20} Exacerbation of psoriasis is probably the most common cutaneous adverse effect that appears during treatment with antimalarials, with some cases described in patients with autoimmune diseases and also with COVID-19. Lesions of plaque psoriasis, pustular psoriasis, inverse psoriasis, and even erythroderma have been described in patients undergoing treatment with chloroquine and hydroxychloroquine.\textsuperscript{21-24} It is important to screen for a personal history of psoriasis in patients with COVID-19 who are candidates for antimalarials to prevent severe flares.\textsuperscript{25} Cutaneous hypopigmentation is another well-known skin adverse effect of antimalarial agents that usually appears after long-term treatment, especially under chloroquine treatment. Melanonychia and mucosal pigmentation can also appear because of the high drug binding of both chloroquine and hydroxychloroquine and frequently arise months or years after the beginning of treatment.\textsuperscript{26-28} Other cutaneous adverse events have been described\textsuperscript{29-31} and are detailed in Table 1\textsuperscript{32-36} with their general approach.

**CAPSULE SUMMARY**

- Severe acute respiratory syndrome coronavirus 2 infection has been associated with multiple cutaneous manifestations, such as maculopapular eruption, pseudo-chilblain lesions, urticaria, monomorphic disseminated vesicular lesions, acral vesicular-pustulous lesions, and livedo or necrosis.
- Many treatments prescribed for COVID-19 may cause a wide variety of cutaneous adverse effects that should be considered in the differential diagnosis.

**LOPINAVIR/РИТОНАВИР**

Lopinavir/ritonavir is an oral agent approved for treating HIV infections. This combination may have a role in the treatment of other coronavirus infections such as SARS-CoV-1 or Middle East respiratory syndrome (MERS) through 3-chymotrypsin–like protease inhibition.\textsuperscript{37,38} Its use in the treatment of COVID-19 is currently being investigated, after observing promising results in case reports and case series.\textsuperscript{39,40} There are more than 30 registered clinical trials involving lopinavir/ritonavir for the treatment of COVID-19,\textsuperscript{10} although the results of 1 trial conducted on adult patients hospitalized with severe COVID-19 did not show significant benefits beyond standard care. In this study, the mean time to start treatment was 13 days.\textsuperscript{41} Cutaneous adverse reactions are among the most common adverse effects in patients treated with lopinavir/ritonavir. According to HIV studies, skin rashes may appear in 5% of adult patients and up to 12% of children. This maculopapular pruritic rash often starts shortly after the start of treatment and is usually well tolerated, although Steven-Johnson syndrome (SJS) associated with serious multiorgan toxicity has been described.\textsuperscript{42-44} In patients with HIV treated with this combination, inflammatory, painful leg edema appearing 3 or 4 weeks after starting the treatment has been described, which might be
associated with skin rash.⁴⁵,⁴⁶ Alopecia areata has also been reported as an infrequent and delayed adverse reaction, and treatment needs to be discontinued for improvement to occur.⁴⁷,⁴⁸ Other cutaneous adverse events⁴⁹-⁵³ are detailed in Table I.

**RIBAVIRIN/INTERFERON**

Systemic ribavirin, a guanine analogue that inhibits RNA polymerase and has been used in chronic hepatitis C virus infection, is currently being investigated as a treatment for COVID-19 in 3 clinical trials,¹⁰ although previous studies in patients with SARS-CoV-1 and MERS showed no significant effectiveness.⁵⁴,⁵⁵ This drug is usually combined with interferon in both hepatitis C virus and in COVID-19 infections because of the activity of interferon against MERS.⁵⁶ Drug-induced skin reactions are among the most common adverse effects of both drugs, and their global incidence has been estimated at 13% to 23%.⁵⁷,⁵⁸ A wide range of cutaneous manifestations have been described⁵⁹-⁶² (Table I).

**OSELTAMIVIR**

Oseltamivir is a neuraminidase inhibitor that was successfully used during the 2010 influenza H1N1 outbreak. At the beginning of the SARS-CoV-2 pandemic, oseltamivir was used in many patients, but recent clinical trials did not show significant effectiveness. It is currently being investigated in 6 clinical trials.¹⁰ Cutaneous adverse effects are unusual, but the appearance of SJS and toxic epidermal necrolysis should be monitored, especially in children.⁶³,⁶⁴

**REMDESVIR**

Remdesivir (GS-5734) is a nucleotide analogue prodrug that inhibits viral RNA polymerases.⁶⁵ It was developed to treat Ebola disease and other RNA viruses,⁶⁶ and it has been shown to have potent in vitro activity against SARS-CoV-2 by interfering with NSP12.¹⁴ Its effectiveness in the treatment of COVID-19 is currently being tested in 11 ongoing randomized trials.¹⁰ It has been approved by the FDA as an Emergency Use Authorization,¹¹ and as of July 3, 2020, the European Commission granted its conditional marketing authorization for the treatment of COVID-19 in adults and adolescents (from 12 years of age and weighing at least 40 kg) with pneumonia requiring supplemental oxygen.¹² Although there is little information on remdesivir adverse events, cutaneous manifestations may not be very frequent. A randomized controlled trial assessing investigational therapies for Ebola disease showed cutaneous adverse events in 1.7% (3/175) of patients treated with remdesivir.⁶⁷ More recently, a cohort of 53 patients receiving a 10-day course of remdesivir were followed up, and 7.55% (4/53) had developed a cutaneous rash.⁶⁸ Nevertheless, no information is provided about rash morphology, distribution, or timeline in relation to remdesivir that may help clinicians differentiate from cutaneous manifestations of COVID-19.⁶⁹ A combination of oral antihistamines and topical corticosteroids could be an effective treatment for this adverse event.

**FAVIPIRAVIR**

Favipiravir (T-705) is an antiviral triphosphate that inhibits RNA polymerase, blocking viral replication. It was approved in Japan for treating pandemic influenza virus infections and was also used off label to treat patients infected with the Ebola virus and the Lassa virus.⁷⁰ It is also currently being considered for the treatment of COVID-19 in 14 clinical trials.¹⁰ To our knowledge, no adverse cutaneous events have been reported to date.⁷¹-⁷³

**DARUNAVIR**

Darunavir, a protease inhibitor used against HIV infections, may also have potential efficacy in treating COVID-19 and is being investigated at this time in 2 clinical trials.¹⁰ Maculopapular rash is a common adverse event associated with darunavir⁷⁵-⁷⁷ and should be differentiated from rashes related to COVID-19.⁶⁹ The median interval between darunavir initiation and rash development is 14 days (range, 1-150 days), and a previous history of rashes linked to non-nucleoside reverse transcriptase inhibitors is a risk factor for darunavir-related rashes.⁷⁵ Although darunavir-related rashes are often self-limiting and usually mild to moderate in severity,⁷⁷,⁷⁸ they can occasionally be severe, without improvement after treatment with oral antihistamines or steroids, in which case it is necessary to discontinue darunavir treatment.⁷⁵ Other cutaneous manifestations are detailed in Table I.⁷⁷-⁷⁹

**IMATINIB**

Imatinib, a tyrosine kinase inhibitor, is another drug that may be effective in treating COVID-19 and that is currently being investigated in 4 clinical
Table I. Adverse cutaneous events related to the most frequently used drugs in COVID-19

| Drug | Morphology of cutaneous eruption | Frequency | Key points for differential diagnosis with skin manifestations of COVID-19 | How to manage the adverse cutaneous effect |
|------|----------------------------------|-----------|-------------------------------------------------------------------------|-------------------------------------------|
| Antimalarials | Pigmentation disorders | 4.9% to 29% | Personal history of psoriasis | Symptomatic (antihistamines ± topical or systemic corticosteroids) in mild to moderate cases |
| | Maculopapular rash | Up to 11.5% | Chronology of drug introduction and onset of symptoms | Treatment discontinuation in severe cases |
| | Exanthematous reactions | | Complete blood count (eosinophilia in DRESS syndrome) | |
| | DRESS syndrome | | Complete metabolic panel to assess renal and liver function may be considered. | |
| | AGEP | | Biopsy in severe cases with diagnostic doubts* | |
| | Psoriasis exacerbations | | | |
| | Erythema multiforme | | | |
| | Systemic eczematous contact dermatitis | | | |
| Lopinavir/ Ritonavir | Maculopapular rash | 5% adults/12% children | Chronology of drug introduction and onset of symptoms (a few days in the case of rash and SJS, 3-4 wk in the case of leg edema) | Symptomatic (antihistamines ± topical or systemic corticosteroids) in mild to moderate cases |
| | SJS | <1% | | Treatment discontinuation in severe cases |
| | Leg edema | | | |
| | Alopecia areata | | | |
| | Skin infections | | | |
| | Exfoliative erythroderma | | | |
| | Lichenoid eruptions | | | |
| | Urticaria | | | |
| | Pruritus | | | |
| | Xeroderma | | | |
| | Oral mucosa lesions | | | |
| | Redistribution of body fat, facial wasting, cysts, and ingrown toenails | Delayed | | |
| Ribavirin +/− interferon | Eczematous drug reactions | 10.3% to 23% | Chronology of drug introduction and onset of symptoms | Symptomatic (antihistamines ± topical or systemic corticosteroids) in mild to moderate cases |
| | Xerosis and pruritus | | Biopsy in severe cases with diagnostic doubts* | Treatment discontinuation in severe cases |
| | Maculopapular rash | 1% to 4% | | |
| | Psoriasis | | | |
| | Lichenoid eruptions | | | |
| | Alopecia | 8.1% to 19% | | |
| Oseltamivir | SJS | <1% | Special attention in children | Treatment discontinuation |
| | TEN | | Chronology of drug introduction and onset of symptoms | |
| Remdesivir | Maculopapular rash | 1.7% to 7.5% | Chronology of drug introduction and onset of symptoms | Symptomatic (antihistamines ± topical or systemic corticosteroids) |
| | | | | |

Continued
| Drug                  | Morphology of cutaneous eruption | Frequency | Key points for differential diagnosis with skin manifestations of COVID-19 | How to manage the adverse cutaneous effect |
|-----------------------|----------------------------------|-----------|--------------------------------------------------------------------------|--------------------------------------------|
| Darunavir             | Maculopapular rash               | ~10%      | Previous history of reactions with non-nucleoside reverse transcriptase inhibitors | Rash is usually self-limiting.            |
|                       | Thrombocytopenic purpura         | <1%       | Chronology of drug introduction and onset of symptoms (median, 14 d in the case of rash) | Symptomatic (antihistamines ± topical or systemic corticosteroids) in mild to moderate cases |
|                       | Vesicular rash                   | <1%       | Biopsy in severe cases with diagnostic doubts*                           | Treatment discontinuation in severe cases |
|                       | Allergic dermatitis              | <1%       |                                                                           |                                            |
|                       | SJS                              | <1%       |                                                                           |                                            |
|                       | TEN                              | <1%       |                                                                           |                                            |
|                       |                                  |           |                                                                           |                                            |
| Imatinib              | Maculopapular rash               | 20% to 67%| Complete blood count (eosinophilia)                                      | In the case of rash, symptomatic treatment with antihistamines and/or topical corticosteroids |
|                       | Edema                            | 48% to 65%| Chronology of drug introduction and onset of symptoms (median, 2.8 mo in the case of rash) | Systemic corticosteroids and modification of the imatinib regimen are not usually necessary. |
|                       | Pigmentary disorders             | 4% to 40% |                                                                           | In other severe cases, treatment discontinuation should be considered. |
|                       | Lichenoid reactions              | <1%       |                                                                           |                                            |
|                       | Psoriasiform eruption            | <1%       |                                                                           |                                            |
|                       | Pityriasis rosea—like eruption   | <1%       |                                                                           |                                            |
|                       | AGEP                             | <1%       |                                                                           |                                            |
|                       | SJS                              | <1%       |                                                                           |                                            |
|                       | Urticaria                        | <1%       |                                                                           |                                            |
|                       | Neutrophilic dermatosis          | <1%       |                                                                           |                                            |
|                       | Photosensitivity                 | <1%       |                                                                           |                                            |
|                       | Porphyria and pseudoporphyria    | <1%       |                                                                           |                                            |
| Tocilizumab           | Maculopapular rash               | >10%: rash, | Chronology of drug introduction and onset of symptoms (rash and urticaria) | Symptomatic (antihistamines ± topical or systemic corticosteroids) in mild to moderate cases |
|                       | Urticaria                        | urticaria, cellitis | Bacterial cultures and imaging tests (cellulitis and necrotizing fasciitis) | Treatment discontinuation in severe cases |
|                       | Cellulitis                       | <1%: necrotizing fasciitis, cutaneous |                                                                           |                                            |
|                       | Necrotizing fasciitis            | fasciitis, cutaneous |                                                                           |                                            |
|                       | Cutaneous sarcoidosis            | sarcoidosis, pustular eruptions | Biopsy in severe cases with diagnostic doubts* | Dosage reduction or treatment discontinuation |
|                       | Pustular eruptions               | pustular eruptions | | Desensitization |
| Anakinra              | Injection site reaction          | 13.8% to 14.6% | Chronology of drug introduction and onset of the symptoms | | |
|                       | Generalized urticarial rash      | <1% to 4% | Vigilance of anakinra dosage | | |
| Immunglobulins        | During the infusion:            | >10%      | Biopsy in severe cases with diagnostic doubts* | During the infusion: stop the infusion and administer oral/intravenous diphenhydramine or corticosteroids. Consider premedication with these drugs in patients with previous reactions |
|                       | Urticarial plaques               |           |                                                                                           |                                            |
|                       | Delayed:                         |           |                                                                                           |                                            |
|                       | Maculopapular rash               | <1%       |                                                                                           |                                            |
|                       | Eczema                           |           |                                                                                           |                                            |
|                       | Erythema multiforme              |           |                                                                                           |                                            |
|                       | Purpuric erythema                |           |                                                                                           |                                            |
| Medication       | Skin Effect                                      | Percentage Range | Additional Information                                                                 |
|------------------|--------------------------------------------------|------------------|----------------------------------------------------------------------------------------|
| Corticosteroids  | Skin thinning                                    | 51% to 73.1%     | Chronology of drug introduction and onset of symptoms                                 |
|                  | Purpura and telangiectasia                        | 7.1% to 23.3%    | Biopsy in severe cases with diagnostic doubts*                                           |
|                  | Hypertrichosis                                    | 15.8% to 39.1%   | Treatment discontinuation when possible                                                 |
|                  | Hair loss                                         | 9.9% to 27.6%    | Acne vulgaris treatment 32 in the case of steroid acne                                  |
|                  | Stretch marks                                     | 7.1% to 23.3%    | Antibiotics/antifungals/antivirals in the case of skin infections                      |
|                  | Risk of skin infections (malassezia folliculitis, cutaneous candidiasis, bacterial cellulitis, or herpes zoster) | ~7%              |                                                                                         |
|                  | Steroid acne (monomorphic follicular papulopustules that favor the chest and back) | 0.3% to 8.7%     |                                                                                         |
| Colchicine       | Alopecia                                          | <1%              | Vigilance of colchicine dosage                                                         |
|                  | Morbilliform rash                                 |                  | Complete blood count and renal function                                                 |
|                  | Bullous dermatitis                                |                  | Biopsy in severe cases with diagnostic doubts* (Although not common, the presence of metaphase-arrested keratinocytes on skin biopsy is useful for the diagnosis) |
|                  | Erythema nodosum—like lesions                     |                  | Dosage reduction or treatment discontinuation                                           |
|                  | TEN-like reactions                                |                  | Supportive care 33,34                                                                  |
| LMWH             | Heparin-induced skin necrosis                     | <1%              | Rapid discontinuation of LMWH (if not, it can lead to fatal complications such as limb ischemia or myocardial or cerebral infarction) |
|                  | (erythematous plaques, hemorrhagic blisters, necrotic ulcers, and petechiae) |                  | and administration of anticoagulants such as danaparoid or argatroban               |
|                  |                                                   |                  | Standard wound care for skin necrosis                                                   |

**Additional Information:**

- AGEP, Acute generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic symptoms; LMWH, low-molecular-weight heparins; SJS, Steven-Johnson syndrome; TEN, toxic epidermal necrolysis.

*In certain circumstances/clinical presentations, a skin biopsy may not be able to differentiate drug versus virus-induced eruption.
Its activity occurs in the early stages of infection, after internalization and endosomal trafficking, by inhibiting the fusion of the virions at the endosomal membrane. More than 20% of patients treated with imatinib may develop a rash, presenting as erythematous and maculopapular lesions. The median time to develop a severe rash requiring major interventions was 2.8 months (range, 0.2-8.4 mo). Serial eosinophil blood levels during imatinib treatment showed direct correlation with the development of erythematous and maculopapular skin rash and its severity. Major interventions, including systemic steroids and imatinib dose modification/reduction, are rarely needed (5%), and discontinuation is extremely rare. Other cutaneous manifestations are detailed in Table I.

**ANTICYTOKINE OR IMMUNOMODULATORY AGENTS**

Different monoclonal antibodies against cytokines potentially involved in the so-called cytokine storm, a dysfunctional stimulation of the immune system leading to organ damage, have been proposed for the management of COVID-19. Tocilizumab, an IL-6 blocker, is the most investigated drug in this field, and it is being used at this time in more than 30 clinical trials. Its cutaneous manifestations may be divided into true cutaneous adverse effects (urticarial, purpuric, and ulcerating lesions) and those secondary to infection. The most common adverse cutaneous reactions to tocilizumab are maculopapular rash, urticaria, and cellulitis. Necrotizing fasciitis, cutaneous sarcoidosis, and pustular eruptions have also been reported. Maculopapular rash and urticarial lesions will be the main diagnostic criteria for skin manifestations of COVID-19. Treatment will require the use of antihistamines and corticosteroids. Although less frequent, the increased risk of skin infections associated with IL-6 blockers should always be considered, because cellulitis and necrotizing fasciitis can be life-threatening conditions that must be adequately and promptly treated.

Anakinra, an IL-1 receptor antagonist, is currently under investigation for use in the treatment of COVID-19-associated pulmonary complications with elevated IL-6 levels. To date, up to 17 clinical trials are investigating its use in COVID-19. A recent retrospective cohort study has shown significant clinical improvement with high doses in patients with COVID-19 with acute respiratory distress syndrome and hyperinflammation. Mild injection site reaction is the most common cutaneous adverse effect during anakinra treatment. However, some investigators have reported the occurrence of severe cutaneous urticarial rash in several patients, which means treatment has to be discontinued. Clinical improvement of the cutaneous rash has been noted after treatment cessation.

**IMMUNOGLOBULIN THERAPY**

Immunoglobulin therapy consists of the use of hyperimmune immunoglobulins or plasma from recovered patients. These antibodies can help clear the free circulating virus and infected cells. Its use in the treatment of COVID-19 is currently being investigated in more than 70 clinical trials, and the FDA is supporting and coordinating research in this field. Cutaneous adverse reactions in the form of urticarial plaques during the infusion are common, whereas delayed skin reactions in the form of eczema, erythema multiforme, purpuric erythema, or maculopapular rash are infrequent. Slowing the infusion rate of immunoglobulin could help reduce infusion reactions. In the presence of compatible infusion-related skin lesions, the infusion should be temporarily discontinued, and treatment with oral/intravenous diphenhydramine or corticosteroids may be administered. Moreover, patients may infrequently develop systemic sensitivity to immunoglobulin therapy, including anaphylaxis/anaphylactic reactions. In patients with skin reactions to previous infusions, premedication with diphenhydramine and/or corticosteroids should be considered. Delayed skin reactions can be safely treated with antihistamines and/or topical or systemic corticosteroids. COVID-19 infection can produce urticarial rash and purpuric erythema, which should be distinguished from these reactions.

**SYSTEMIC CORTICOSTEROIDS**

Data on the use of systemic corticosteroids in COVID-19 infection are controversial, although they have been proposed to control the cytokine storm and are also required for shock or exacerbation of chronic obstructive pulmonary disease. Their use is currently being investigated in more than 15 clinical trials. Recently, the preliminary results of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial showed that dexamethasone compared to standard care reduced 28-day mortality by a third in patients receiving invasive mechanical ventilation and by a fifth in patients receiving oxygen without invasive mechanical ventilation; the mortality rate did not change in patients not receiving respiratory support. The most common adverse cutaneous events, most of them largely delayed, and their general approach are detailed in Table I. With regard to differential diagnosis of cutaneous manifestations of COVID-19, the vascular fragility
associated with corticosteroid use, especially in elderly patients, may be similar to the thrombotic complications of COVID-19 infection.\textsuperscript{108,109}

**COLCHICINE**

Colchicine has been proposed for the treatment of COVID-19.\textsuperscript{110} It is currently being investigated for the treatment of COVID-19 in more than 10 clinical trials.\textsuperscript{10} Cutaneous adverse events with colchicine are very infrequent, mainly occurring because of intoxication (Table I).\textsuperscript{111-115}

**LOW-MOLECULAR-WEIGHT HEPARINS**

Low-molecular-weight heparins are recommended for all in-patients to prevent thrombotic complications,\textsuperscript{110} and more than 15 clinical trials are investigating their use in COVID-19 at this time.\textsuperscript{10} Heparin-induced skin necrosis is the most important adverse cutaneous event\textsuperscript{117} (Table I). Lesions can occur at the injection site or at a distance.\textsuperscript{118} The diagnosis is usually clinical. Other complementary tests and management are detailed in Table I.

**CONCLUSIONS**

This new virus is encouraging physicians and scientists to expand their knowledge and describe new findings associated with the disease, including in the field of dermatology. Moreover, the number of investigational drugs is increasing daily. By considering adverse drug reactions in the differential diagnosis, dermatologists can be useful in assisting in the care of these patients. Although the frequency of drug eruption in patients with COVID is currently unknown, drugs may be the causal agent of skin reactions in some patients. There are a variety of skin reactions, some of which may be confused with cutaneous manifestations of COVID-19. Diagnosis is usually clinical, and skin biopsy or other complementary tests are generally reserved for severe cases. Management is often symptomatic, but it is sometimes necessary to modify or discontinue the treatment, and some conditions can even be life-threatening.

We want to thank Charlotte Bower for improving the English of the manuscript.

**REFERENCES**

1. Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315-331.

2. Sanders JM, Monogue ML, Jodkowski TZ, Cutrell JB. Pharmacoologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. April 13, 2020. https://doi.org/10.1001/jama.2020.6019.

3. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730-1741.

4. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34:e244-e245.

5. van de Bor M. Fetal toxicology. Handb Clin Neurol. 2019;162:31-55.

6. Galván Casas C, Catalá A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71-77.

7. Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. Comment on: cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol. 2020;34:e252-e254.

8. van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34:e300-e301.

9. Peroni A, Colato C, Schena D, Girolomoni G. Urticarial lesions: if not urticaria, what else? The differential diagnosis of urticaria: part I. Cutaneous diseases. J Eur Acad Dermatol Venereol. 2010;62(4):541-555.

10. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/. Accessed June 7, 2020.

11. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed May 20, 2020.

12. European Medicines Agency. COVID-19: what’s new [cited 2020 May 20]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-whats-new.

13. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:732-739.

14. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-271.

15. Mehra MR, Ruschitzka F, Patel AN. Retraction—hydroxychloroquine or chloroquine with or without a Macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395:1820.

16. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(26):2582.

17. Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018;78(1):100-106.e1.

18. Matsuda T, Ly NTM, Kambe N, et al. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: a case report and review of the published work. J Dermatol. 2018;45(3):344-348.

19. Schwartz RA, Janniger CK. Generalized pustular figurate erythema: a newly delineated severe cutaneous drug reaction linked with hydroxychloroquine. Dermatol Ther. 2020;33(3):e13380.
20. Takamasu E, Yokogawa N, Shimada K, Sugii S. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption. Lupus. 2019;28(12):1473-1476.

21. Kuttu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther. 2020. https://doi.org/10.1111/dth.13383.

22. Shindo E, Shikano K, Kawazoe M, et al. A case of generalized pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus. Lupus. 2019;28(8):1017-1020.

23. Ullah A, Zeb H, Khakwani Z, Murphy FT. Hydroxychloroquine-induced inverse psoriasis. BMJ Case Rep. 2019;12(2):e224619.

24. Wang W-M, Wang KY, Wang T, Jin H-Z, Fang K. Hydroxychloroquine-induced pustular psoriasis caused by hydroxychloroquine in a patient with systemic lupus erythematosus. Chin Ed J. 2018;131(15):1887-1888.

25. Gravani A, Gaitanis G, Zografi A, Bassukas ID. Synthetic antimalarial drugs and the triggering of psoriasis—do we need disease-specific guidelines for the management of patients with psoriasis at risk of malaria? Int J Dermatol. 2014;53(3):327-330.

26. Schroeder RL, Gerber JP. Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies. Toxicol Rep. 2014;1:963-968.

27. Bahloul E, Jallouli M, Garbaa S, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus. 2017;26(12):1304-1308.

28. Cacoub P, Amoura Z, Cосттадо-Чалумеу N, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol. 2013;149(8):935-940.

29. Girijala RL, Siddiqi I, Kwak Y, Wright D, Patel DB, Goldberg LH. Pustular DRESS syndrome secondary to hydroxychloroquine with EBV reactivation. J Drugs Dermatol. 2019;18(2):207-209.

30. Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Cutis. 2016;97(3):212-216.

31. Pérez-Ezquerro PR, de Barrio Fernández M, de Castro Martínez FJ, Ruiz Hornillos FJ, Prieto García A. Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient. Allergol Immunopatol (Madr). 2006;34(4):174-175.

32. Zaalenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.

33. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med. 2015;128(5):461-470.

34. Schutter S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28.

35. Sator P, Kiprova A, Feldmann R, Breier F, Steiner A. Heparin-induced skin necrosis. J Eur Acad Dermatol Venereol. 2016;30(1):161-163.

36. Warkentin TE, Greinacher A. Management of heparin-induced thrombocytopenia. Curr Opin Hematol. 2016;23(5):462-470.

37. Rabaan AA, Alahmed SH, Bazzi AM, Alhami HM. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol. 2017;66(9):1261-1274.

38. Hui DSC. An overview on severe acute respiratory syndrome (SARS). Monaldi Arch Chest Dis. 2005;63(3):149-157.

39. Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79.

40. Ye X-T, Luo Y-L, Xia S-C, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(19):3390-3396.

41. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.

42. Calista D. Maculo-papular rash induced by lopinavir/ritonavir. Eur J Dermatol. 2005;15(2):97-98.

43. Rudin C, Burri M, Shen Y, et al. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children. Pediatr Infect Dis J. 2008;27(5):431-437.

44. Manfredi R, Sabbatani S. Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function. AIDS. 2006;20(18):2399-2400.

45. Eyer-Silva WA, Neves-Motta R, Pinto JFC, Morais-De-Sá CA. Inflammatory oedema associated with lopinavir-including HAART regimens in advanced HIV-1 infection: report of 3 cases. AIDS. 2002;16(4):673-674.

46. Lascaux AS, Lepirt P, Bertič M, Levy Y. Inflammatory oedema of the legs: a new side-effect of lopinavir. AIDS. 2001;15(6):819.

47. Chrysos G, Mikros S, Kokkoris S, Pastelli A, Kontochristopoulos G. Alopoeica induced by lopinavir plus ritonavir therapy in an HIV patient. J Drugs Dermatol. 2007; 6(7):742-743.

48. Bongiovanni M, Chiesa E, Monforte AdA, Bini T. Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART. Dermatol Online J. 2003;9(5):28.

49. Türens Ü, Türens B, Lotti T. Cutaneous side-effects of the potential covid-19 drugs. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13476.

50. Stauber RE, Fauler G, Rainer F, et al. Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus. Wien Klin Wochenschr. 2017;129(21-22):848-851.

51. Scully C, Díz Dios P. Orafacial effects of antiretroviral therapies. Oral Dis. 2001;7(4):205-210.

52. Achan J, Kakuru A, Ikizezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012;367(22):2110-2118.

53. James CW, McNelis KC, Cohen DM, Szabo S, Bincsik AK. Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy. Ann Pharmacother. 2001;35(7-8):881-884.

54. Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837-1844.

55. Stockman LJ, Bellamy R, Garner P, SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.

56. Morra ME, Van Thanh L, Kamel MG, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: a systematic review and meta-analysis. Rev Med Virol. 2018;28(3):e1977.

57. Kerk K, Negro F, Lübbe J. Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. Br J Dermatol. 2003;149(3):656.
58. Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oliva N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alpha and ribavirin for chronic hepatitis C: the value of an interdisciplinary assessment. Br J Dermatol. 2004;150(5):1046-1047.

59. Patrk I, Morovič M, Markulin A, Patrk J. Cutaneous reactions in patients with chronic hepatitis C treated with peginterferon and ribavirin. Dermatology. 2014;228(1):42-46.

60. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009;23(10):677-683.

61. Patel P, Malik K, Krishnamurthy K. Cutaneous adverse events in chronic hepatitis c patients treated with direct-acting antivirals: a systematic review and meta-analysis. J Cutan Med Surg. 2016;20(1):58-66.

62. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012;56(2):455-463.

63. Bergstrom KG. Tamiflu: what dermatologists need to know. J Drugs Dermatol. 2010;9(1):76-78.

64. Oseltamivir: cutaneous and neurological adverse effects in children. Prescrire Int. 2006;15(85):182-183.

65. Tchensokov EP, Feng JY, Porter DP, Gotte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):326.

66. World Health Organization. WHO R&D blueprint: ad-hoc expert consultation on clinical trials for Ebola therapeutics. 2018. http://www.who.int/ebola/drc-2018/summaries-of-evidence-experimental-therapeutics.pdf?ua=1. Accessed April 20, 2020.

67. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-2303.

68. Grein J, Ohmagari N, Shin D, et al. compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327-2336.

69. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(S1):e212-e213.

70. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85-94.

71. Costanzo M, De Giglio MAR, Roviello GN. SARS CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem. 2020;27:4536-4541.

72. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT Jr, et al. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375(15):1448-1456.

73. Sissoko D, Lauouenan C, Folkesson E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):E1001967.

74. Dong L, Hu S, Gao J. discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.

75. Lin KY, Cheng CY, Yang CJ, et al. Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factors. J Infect Chemother. 2014;20(8):465-470.

76. Pernas B, Grandal M, Tabernilla A, et al. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain. J Med Virol. 2016;88(12):2125-2131.

77. Tashkina K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.

78. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62(5):879-888.

79. Pakh R, Azu MC, Taiira BR, Sandoval S. Antiretroviral-induced toxic JGermal necrolysis in a patient positive for human immunodeficiency virus. Clin Exp Dermatol. 2009;34(8):e775-e777.

80. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frierman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol. 2016;90(19):8924-8933.

81. Park SR, Ryu MH, Ryoo BY, et al. Severe imatinib-associated skin rash in gastrointestinal stromal tumor patients: management and clinical implications. Cancer Res Treat. 2016;48(1):162-170.

82. Di Tullio F, Mandel VD, Scotti R, Padalino C, Pellacani G. Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature. Int J Dermatol. 2016;55(7):784-790.

83. Martinez-Mera C, Capusan TM, Herrera-Moyano M, Urquia Renke A, Steegmann Olmedillas JL, de Argila D. Imatinib-induced pseudoporphyria. Clin Exp Dermatol. 2018;43(4):463-466.

84. Penn EH, Chung HJ, Keller M. Imatinib mesylate-induced lichenoid drug eruption. Cutis. 2017;99(3):189-192.

85. Pretel-Irazabal M, Tuneu-Valls A, Ormaechea-Perez N. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. Actas Dermosifiliogr. 2014;105(7):655-662.

86. Shi CR, Nambudiri VE. Imatinib-induced psoriasisiform eruption in a patient with chronic myeloid leukemia. Am J Hematol. 2018;93(3):467-468.

87. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

88. Szekalića A, Majewski D, Puszczewicz M. Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy. Reumatologia. 2019;57(4):214-220.

89. Kremer JM, Blanco R, Halland AM, et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clin Exp Rheumatol. 2016;34(4):625-633.

90. Mysler E, Cardiel MH, Xavier RM, Lopez A, Ramos-Esquível A. Subcutaneous tocilizumab in monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs in Latin American patients with moderate to severe active rheumatoid arthritis: a multicenter, phase IIIb study. J Clin Rheumatol. 2020. https://doi.org/10.1097/RHU.0000000000001361.

91. Del Giorno R, Iodice A, Mangas C, Gabbuti L. New-onset cutaneous sarcoidosis under tocilizumab treatment for giant cell arteritis: a quasi-paradoxical adverse drug reaction. Case report and literature review. Ther Adv Musculoskelet Dis. 2019;11:1759720x19841796.

92. Rosa-Gonalves D, Bernardes M, Costa L. Necrotizing fasciitis in a patient receiving tocilizumab for rheumatoid arthritis—case report. Reumatol Clin. 2018;14(3):168-170.
93. Mori T, Yamamoto T. Tocilizumab-induced pustular drug eruption. Int J Rheum Dis. 2017;20(11):1776-1777.
94. Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-e331.
95. Bettiol A, Silvestri E, Di Scala G, et al. The right place of interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. Intern Med J. 2017;47(9):1086-1088.
96. Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, et al. Efficacy of anakinra in refractory adult-onset Still’s disease: multicenter study of 41 patients and literature review. Medicine. 2015;94(39):e1554.
97. Orlando I, Vitale A, Rigante D, Lopalco G, Fabiani C, Cantarini L. Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. Intern Med J. 2017;47(9):1086-1088.
98. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398-400.
99. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA coordinates national effort to develop blood-related therapies for COVID-19. [cited 2020 May 20]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-coordinates-national-effort-develop-blood-related-therapies-covid-19.
100. US Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma. [cited 2020 May 20]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exempt-indication-on-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.
101. Miyamoto J, Böckle BC, Zillikens D, Schmidt E, Schmuth M. Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. JAMA Dermatol. 2014;150(10):1120-1122.
102. Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin: a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139-145.
103. Brennan V, Salome-Bentley N, Chapel H. Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133(2):247-251.
104. Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71-81.
105. Najarian DJ. Morbilliform exanthem associated with COVID-19. JAA AAD Case Rep. 2020;6:493-494.
106. Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol. 2020;34(6):e246-e247.
107. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Effect of dexamethasone in hospitalized patients with COVID-19—preliminary report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021436.
108. Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones OM, Fernandez-Nieto D. Reply to “COVID-19 can present with a rash and be mistaken for Dengue”: petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol. 2020;83:e141-e142.
109. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020;83:700.
110. Poti F, Pozzoli C, Adami M, Poli E, Costa LG. Treatments for COVID-19: emerging drugs against the coronavirus. Acta Biomed. 2020;91(2):118-136.
111. Combaila A, Balliu-Fiqué C, Fortea A, Ferrando J. Anagen effluvium following acute colchicine poisoning. Int J Trichol. 2016;8(4):171-172.
112. Gürkan A, Oğuz MM, Boduroğlu Cengiz E, Şenel S. Dermatologic manifestations of colchicine intoxication. Pediatr Emerg Care. 2018;34(7):e131-e133.
113. Güven AG, Bahat E, Akman S, Artan R, Erol M. Late diagnosis of severe colchicine intoxication. Pediatrics. 2002;109(5):971-973.
114. Mason SE, Smoller BR, Wilkerson AE. Colchicine intoxication diagnosed in a skin biopsy: a case report. J Cutan Pathol. 2006;33(4):309-311.
115. Arroyo MP, Sanders S, Yee H, Schwartz D, Kamino H, Strober BE. Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. Br J Dermatol. 2004;150(3):581-588.
116. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-1026.
117. Adya KA, Inamadar AC, Palit A. Anticoagulants in dermatology. Indian J Dermatol Venereol Leprol. 2016;82(6):626-640.
118. Yu TT, Gooderham M. Adverse drug reactions and cutaneous manifestations associated with anticoagulation. J Cutan Med Surg. 2017;21(6):540-550.